Since the first approved gene therapy trial was started by WF Anderson's group on 22 May 1989, the number of gene therapeutic studies has increased rapidly. Most of these studies, however, suffer from low gene transfer efficiencies and expression levels. To overcome this problem new transduction protocols and improved vector systems should be developed. This is a labor-intensive and time-consuming process, especially with respect to viral vectors, where new producer cell lines should be established. The recent introduction of a new generation of marker genes, allowing for rapid and convenient determination of gene transfer efficiencies by flow cytometry, represents an important step in the development of the basics of gene therapy.
Classical marker genes rely on the transfer of a selective advantage to the target cells, ie they allow the in vitro selection of transduced cells conferring cellular resistance to cytotoxic drugs. However, this method is limited by the necessity for prolonged in vitro selection and nonspecific toxicity of the drugs used for selection. Neomycin phosphotransferase (neo R ) is the most frequently used and best characterised marker gene. In bacteria, from where it originated, it confers resistance to the antibiotic, kanamycin. Transduced eukaryotic cells are resistant to the neomycin analogue G418. The excellent selection characteristics and the low in vitro toxicity allow for a broad application of neo R . The most interesting property is its ability to identify one positive cell out of millions of nontransduced cells. Most of the clinical gene marking trials, but also the therapeutic studies use vectors encoding the neo R gene. 1 However, despite its historical merits neo R has many disadvantages: G418 selection usually requires about 5 days, and the necessary concentration of the drug should be individually determined for each target cell. Selection with G418 does not indicate the strength of gene expression. Suppression of neo R expression during cell culture has been shown. Finally, there are several reports of in vivo toxicity 1 of the gene product of neo R , at least partially due to its immunogenicity.
Other methods to determine gene transfer include PCR or in vitro, ex vivo, or in situ staining with substrates for the bacterial ␤-galactosidase (␤-gal) or the human placental alkaline phosphatase (AP). The PCR approach is very sensitive even when only small cell numbers are available, but it does not provide information regarding the level of gene expression. Although the latter methods permit the determination of both the number of positive cells and the strength of the used expression cassette, they often have the disadvantage of high background levels. Moreover, some of those approaches require fixation before measurement. 2 The 'third generation' of marker genes relies on the detection of the transfer marker by flow cytometry (FACS). Consequently, any surface antigen can be principally applied as a transfer marker. Alternatively, autofluorescing proteins may also be useful. However, several requirements should be met. First, the marker should not be expressed at any developmental stage of the target cell. For practical reasons, markers which are normally expressed on only a very limited number of cells, eg differentiation markers, would be preferable. Alternatively, genes from other species could be used. Second, the ectopic expression of the transfer marker should not be toxic to the target cell, neither directly nor indirectly (altered signal transduction etc). For a possible clinical application, the relevant markers should also lack toxicity and immunogenicity in vivo. Third, good monoclonal antibodies should exist for the surface proteins leading to a strong fluorescence shift during FACS analysis.
Several surface antigens such as human and murine CD24, murine CD2, human CD4, the multidrug resistance gene mdr-1 and the full-length or intracytoplasmatically truncated human low-affinity nerve growth factor receptor (LNGFR and ⌬LNGFR) have been used as gene transfer markers. 3 Recently, the autofluorescing green fluorescent protein (GFP) has also found broader application.
The ectopic expression of surface antigens allows the rapid determination of the numbers of transduced cells using antibody-staining and subsequent FACS analysis without prior fixation. Modern flow cytometers can simultaneously analyse up to four different fluorescences, ie multiparameter FACS can be used to define not only the transduced cells but also their current state (eg lineage markers). 2 In addition, transduced cells can be selectively enriched using fluorescence-activated cell sorting or immunoadhesion techniques involving magnetic beads or biotin-streptavidin. The positive and negative cell fractions can be subsequently analysed and compared for their developmental stage and functional properties. 3 Taken together, all of this additional information about the targeted cells opens the way for the accurate improvement of current gene transfer protocols.
The use of selectively enriched cells has many applications for gene therapy. The enrichment procedure based on surface markers takes only a few hours and does not require long-term in vitro cultivation, as for instance G418 selection. Consequently, it minimises the stress to the cell and the possibility of in vitro changes, eg differentiation. This led to the use of the ⌬LNGFR system in a clinical graft-versus-leukemia study by Bonini et al. 4 Recently, Pawliuk et al 5 showed that haematopoiesis in mice can be regenerated almost exclusively with provirally marked cells after FACS-based enrichment. For that purpose, they used human CD24 as a transfer marker, expression of which was shown in all haematopoietic lineages for a minimum of 6 months post-transplant.
Flow cytometry facilitates not only the rapid determination of the number of 'positive' cells but also the analysis of the expression strength of the transgene within a well-defined cell as compared with other transduced cells. This may have a great impact on the improvement of vector systems. In addition, detection and subsequent selection of single producer cells with the highest antigen output allows the establishment of high-titer vector-producer clones within relatively short periods of time compared with the time-consuming search for high producers when using, for example, G418 selection.
The use of allogeneic surface antigens should prevent the triggering of an immune response against the transfer marker. This ensures the long-term survival of the genetically modified cells, a major prerequisite for many gene therapeutic approaches.
The probable lack of immunogenicity makes human surface antigens an interesting alternative for clinical gene therapy studies. However, little is known about biologic in vivo effects of such a strategy. Aberrant expression of surface proteins may lead to unwanted cell trafficking or cell-to-cell interactions. 1 Other possible direct or indirect toxic effects on target cells are discussed below, for example with ⌬LNGFR.
In in vitro experiments with ⌬LNGFR transduced CD34 + cells we did not see any evidence for a toxic sideeffect on colony formation in the absence of nerve growth factor (NGF).
3 NGF was, however, suggested to play a role during different stages of hematopoiesis via its highaffinity receptor TrkA. 6 Obviously, NGF may also bind to the introduced truncated low-affinity receptor. Consequently, if overexpressed, ⌬LNGFR could possibly act as an NGF-antagonist competing for its binding, or aggregating with other receptor units creating nonfunctional oligomers. Further in vitro studies on the influence of NGF on transduced hematopoietic cells are thus necessary.
One of the major complaints using surface antigens is the high number of false positive cells reported by different authors. 7 Compared with nontransduced cells, these cells show significantly higher antibody binding as measured by flow cytometry, but they lack integrated vector. This problem can be overcome, at least in part, by choosing later time-points for the flow cytometry, and setting appropriate borders. 3 The mechanism which causes the occurrence of the surface marker on nontransduced target cells is not yet well understood, although protein transfer is possibly the main cause. This leads to another concern regarding the in vivo use of surface markers, such as ⌬LNGFR. If ⌬LNGFR is shed by infected cells in the neighborhood of nerve cells, this could probably result in strong local antagonistic effects. First clinical studies with ⌬LNGFR-expressing T cells did not reveal any short-term toxic effect, 4 but short-term effects may anyway not be very likely. A possible way to overcome these problems is the development of new variants of ⌬LNGFR lacking NGF binding. This, however, may result in immunogenicity.
The ideal gene transfer marker would thus be a nonimmunogenic surface antigen not expressed on any cell type and lacking any physiological function. As long as we do not have this representative, we should try to exploit and optimise the existing markers. Their short, but successful history indicates that they will have an important role in the further development of gene therapy.
